Articles

Japan Patent Office Sequence Listing Requirements: JPO Filing Guide

If you are filing a patent application involving biological sequences in Japan, understanding the JPO sequence listing requirements is not optional, it is essential. The Japan Patent Office (JPO) has specific, well-defined rules for how nucleotide and amino acid sequences must be presented, formatted, and submitted. Failure to comply with these requirements can delay your application, trigger office actions, or even result in rejection. This guide is designed to help patent applicants, IP professionals, and biotech researchers navigate the jpo sequence listing requirements with clarity and confidence.

What Is a Sequence Listing and Why Does JPO Require It?

A sequence listing is a standardized document that formally presents all nucleotide and amino acid sequences disclosed in a patent application. When your invention involves biological sequences, such as DNA, RNA, or proteins, the JPO requires you to submit this information in a specific structured format.

The purpose is straightforward. The JPO uses sequence listings to:

Enable patent examiners to conduct prior art searches efficiently
Ensure that all sequence data is machine-readable and searchable
Maintain consistency with international patent databases
Allow cross-referencing with global sequence databases like GenBank and EMBL

The jpo sequence listing requirements are rooted in international standards but come with Japan-specific nuances that applicants must understand before submission.

Core JPO Sequence Listing Requirements You Must Know

The JPO aligns its sequence listing rules primarily with the WIPO Standard ST.26, which became mandatory globally in July 2022. This replaced the older ST.25 standard. Here is what you need to know about the core jpo sequence listing requirements under ST.26:

File Format Requirements

Sequence listings must be submitted in XML format as per WIPO ST.26
The file must be a single, self-contained XML document
The XML must conform to the DTD (Document Type Definition) provided by WIPO
File naming must follow the JPO-specified conventions, typically including the application number

Sequence Threshold and Inclusion Rules

All sequences of 10 or more nucleotides must be included in the listing
All sequences of 4 or more amino acids must be included
Sequences that are partially unknown or contain non-standard residues must still be listed using defined placeholders
Sequences that are only mentioned as prior art do not need to be included unless they are also claimed

Language and Content Standards

The sequence listing XML file itself must use English for all coded fields and annotations
Free text qualifiers may be submitted in Japanese or English
Each sequence must be assigned a unique SEQ ID NO referenced consistently throughout the patent description and claims
The applicant name, invention title, and filing details must appear in the header section of the XML file

How to Submit a Sequence Listing to the JPO?

Understanding the jpo sequence listing requirements also means knowing how and when to submit. The JPO offers multiple submission pathways, and each has its own set of procedural steps.

Electronic Filing via J-PlatPat and JPO Online System

The JPO strongly encourages electronic submission through its online patent filing system. When filing electronically:

The sequence listing XML file is uploaded as a separate attachment to the main application
The system automatically validates the XML against ST.26 schema
Any validation errors must be corrected before submission is accepted
You must reference the sequence listing in the body of your description by stating it forms part of the application

Physical and Optical Media Submission

In rare cases where electronic submission is not feasible, the JPO accepts sequence listings on optical media such as CD-ROM or DVD. However:

The disc must be clearly labeled with the applicant name, application number, and date
A written statement confirming the content of the disc must be submitted alongside the application
The JPO discourages this route due to processing delays and recommends electronic submission in all cases

Incorporation by Reference

Japan allows sequence listings to be incorporated by reference in certain circumstances. If a sequence listing was previously submitted in a priority application, you may reference it directly. However, you must confirm that:

The referenced listing complies with current ST.26 standards
A certified copy of the priority application is available to the JPO
No amendments have been made that alter the sequences beyond the original disclosure

Common Mistakes That Lead to Non-Compliance

Even experienced patent filers make errors when dealing with jpo sequence listing requirements. Here are the most frequent pitfalls:

Using the outdated ST.25 format: Since July 2022, ST.25 text files are no longer accepted. All new applications must use ST.26 XML.

Mismatched SEQ ID NOs: The sequence identifiers in your XML file must match exactly with those cited in the claims and description. Any inconsistency will trigger an office action.

Missing sequences: Applicants sometimes overlook short sequences or fragments. Remember, any sequence of 10 or more nucleotides or 4 or more amino acids must be included.

Incorrect free text annotations: Qualifiers like gene names, organism names, and feature descriptions must follow controlled vocabulary where required by ST.26.

File size and encoding errors: Large sequence listings must still be submitted as a single XML file. UTF-8 encoding is mandatory and must be declared in the XML header.

JPO-Specific Rules That Differ from Other Patent Offices

While the jpo sequence listing requirements largely follow WIPO ST.26, Japan has a few jurisdiction-specific rules that set it apart:

Japanese language support in descriptions: Unlike the EPO, the JPO allows the main patent description to be written in Japanese, while the sequence listing XML remains in English coded fields.

Divisional applications: When filing divisional applications at the JPO, the sequence listing from the parent application must be resubmitted in full unless explicitly exempted by the examiner.

Correction procedures: If a sequence listing error is discovered after filing, the JPO allows corrections under specific conditions, but these must be filed promptly and must not introduce new matter into the application.

Translation requirements for PCT entries: When entering the national phase in Japan via the PCT route, the sequence listing does not require Japanese translation, but the description and claims do.

Tools and Resources for Preparing JPO-Compliant Sequence Listings

Preparing a compliant sequence listing is a technical task that requires the right tools. For meeting jpo sequence listing requirements, the following resources are widely used:

WIPO Sequence (WIPO-Seq): A free software tool developed by WIPO that helps create and validate ST.26-compliant XML sequence listings. It supports import from common formats like FASTA and GenBank.

PatentIn and BiSSAP: Legacy tools that supported ST.25 are being phased out. Always use tools that explicitly support ST.26 for any new filings.

JPO’s Official Examination Guidelines: The JPO publishes detailed examination guidelines in both Japanese and English that cover sequence listing compliance in depth. Checking these before filing is strongly recommended.

Professional Sequence Listing Services: For complex applications involving hundreds of sequences, working with a professional service specializing in patent sequence listings can save time and reduce compliance risk significantly.

Final Checklist Before You File

Before submitting your application to the Japan Patent Office, run through this compliance checklist to ensure your sequence listing is ready:

Confirm your file is in ST.26 XML format
Validate the XML using WIPO-Seq or an equivalent validator
Verify all SEQ ID NOs match between the XML and the patent text
Ensure sequences of 10 or more nucleotides and 4 or more amino acids are included
Check that organism names follow NCBI taxonomy conventions
Confirm the applicant name and invention title in the XML header match the main application
Ensure UTF-8 encoding is declared in the XML header

Conclusion

Navigating the jpo sequence listing requirements requires attention to both international standards and Japan-specific rules. Whether you are filing a domestic application or entering the Japanese national phase through the PCT, getting your sequence listing right from the start is critical to a smooth examination process. By following WIPO ST.26 standards, using validated tools, and staying aware of JPO-specific procedural rules, you can avoid common pitfalls and ensure your biological sequence patent application moves forward without unnecessary delays.

For expert assistance with sequence listing preparation, formatting, and compliance, visit The Sequence Listing for professional support tailored to global patent filing requirements.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.